Patents Examined by Shafiqul Haq
  • Patent number: 10634669
    Abstract: This invention discloses “Artificially Cleaved Epitope (ACE)” methods, antibodies, reagents, immunoassays, and kits for designing and detecting mutation-specific epitopes/antigens. The ACE methods can detect epitopes that are either absent or poorly recognizable or accessible naturally to antibodies, and thus must be specifically and artificially created (free terminals) and/or exposed in samples and sample preparations for antibody detection. The ACE methods comprise ACE antigen design and ACE antigen detection. The ACE methods, antibodies, reagents, immunoassays, and kits are useful in research and discovery, diagnostic, and therapeutic applications. In another aspect, the ACE methods can artificially and specifically expose hidden antigens while reducing the antibody non-specific bindings in all antibody-based applications.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: April 28, 2020
    Inventors: Chunli Liu, Bingren Hu
  • Patent number: 10626349
    Abstract: The invention provides surfactant compounds of formulas I-IX, which can be used in methods for aiding the solubilization, digestion, preparation, analysis, and/or characterization of biological material, for example, proteins or cell membranes. The compounds can also aid in the recovery of peptides generated during protein digestion, particularly for in-gel digestion protocol. Additionally, the compounds can improve enzymatic protein deglycosylation without interfering with downstream sample preparation steps and mass spectrometric analysis. The compounds can be specifically useful as digestion aids that can be decomposed by an acid, by heat, or a combination thereof. Decomposition of the surfactants allows for facile separation from isolated samples, and/or allows for analysis of the sample without interfering with the sensitivity of various analytical techniques.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: April 21, 2020
    Assignee: Promega Corporation
    Inventors: Sergei Saveliev, Daniel Simpson, Keith V. Wood, Harry Tetsuo Uyeda, Carolyn Woodroofe Hitko, Dieter Klaubert
  • Patent number: 10618907
    Abstract: Provided herein are cell-permeable, cell-compatible, and chemoselectively-cleavable linkers for tethering (e.g., covalently) functional elements (e.g., a cellular interaction element and a capture element), and methods of use (e.g., intracellular capture and extracellular release of cellular targets) therewith.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: April 14, 2020
    Assignee: PROMEGA CORPORATION
    Inventors: Sergiy Levin, Rachel Friedman Ohana, Thomas Kirkland, Keith V. Wood
  • Patent number: 10620217
    Abstract: Methods for in situ detecting proximity of two targets of interest featuring an antibody conjugated with a cleavable bridge component having a detectable moiety and an antibody conjugated with a non-cleavable bridge component. The bridge components each have a chemical ligation group adapted to form a covalent bond under particular conditions and when the targets are in close proximity. Following covalent bond formation, the cleavable bridge component can be cleaved from the antibody, effectively transferring the detectable moiety to the non-cleavable bridge component. Detection of the detectable moiety is indicative of the targets being in close proximity. The methods are compatible with both chromogenic and fluorogenic detection systems. The methods may be used to perform assays wherein one or more than one proximity event is detected on the same slide.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: April 14, 2020
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Rui Hong
  • Patent number: 10598671
    Abstract: The present application provides stable peptide-based IL-17F capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: March 24, 2020
    Assignees: Indi Molecular, Inc., California Institute of Technology
    Inventors: James R. Heath, Heather Agnew, Blake Farrow, David Bunck, Jingxin Liang, Arundhati Nag, Samir Das, Bert Tsunyin Lai, Suresh Mark Pitram
  • Patent number: 10591469
    Abstract: The present invention is intended to provide an immunoassay method that enables an immunoassay with high sensitivity at a high development rate without causing aggregation of insoluble carriers or non-specific reaction while improving test efficiency and reducing labor. The present invention relates to an immunoassay method that uses a test device, and the method includes: extracting an antigen of a detection target in an analyte with an extraction agent; and detecting the detection target with a detection reagent capable of binding the antigen. The extraction agent is a nitrous acid generated on the test device by a contact reaction between a nitrite salt and a heterocyclic compound having at least one skeleton selected from the group consisting of a cyclic ester, a cyclic amide, and a cyclic imide.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: March 17, 2020
    Assignee: TANAKA KIKINZOKU KOGYO K.K.
    Inventors: Yuya Kato, Hisahiko Iwamoto
  • Patent number: 10585088
    Abstract: Processes and compositions are described for preparing new, colloidally stable, coated nanomagnetic particles useful for both in-vitro and in-vivo biomedical applications, including cell targeting and capturing cells, microorganisms, and cellular organelles or entities such as exosomes. These nanomagnetic particles can also be used as imaging contrast agents due to their small size and high magnetic moment. The nanomagnetic particles include a series of sequentially added, stabilizing surface coatings rendered onto nano-sized magnetic crystal clusters (e.g., magnetite particles) to impart colloidal stability in complex biological samples with minimal leaching of the coating materials, high binding capacity, and low non-specific binding. Another benefit of this invention is the ability to utilize both external and internal magnetic field-generating separation devices to effect separation of the magnetic nanoparticles.
    Type: Grant
    Filed: April 30, 2016
    Date of Patent: March 10, 2020
    Assignee: BioLegend, Inc.
    Inventors: Dhanesh Gohel, Hong Zhang, John Ransom
  • Patent number: 10570216
    Abstract: The present disclosure provides isolated antibodies that bind to acetaminophen-protein adducts that are useful in the detection and diagnosis of acetaminophen-induced toxicity.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: February 25, 2020
    Assignees: BioVentures, LLC, Arkansas Children's Research Institute
    Inventors: Dean W. Roberts, Laura James, Jack Hinson
  • Patent number: 10562978
    Abstract: The invention includes monoclonal and polyclonal antibodies, and antigen-binding fragments thereof, having specific binding affinity for 4,6-diamino-5-(formylamino)pyrimidine (FAPY-adenine); hybridomas producing such antibodies; immunoconjugates comprising an antibody or antigen-binding fragment of the invention coupled to a moiety; and in vitro and in vivo methods for using such antibodies, antibody fragments, and conjugates based on binding to FAPY-adenine; nucleic acids encoding the heavy and/or light chains of the antibodies; vectors comprising the nucleic acid sequences encoding the heavy and/or light chains; host cells comprising and, optionally, expressing the nucleic acid sequences; and methods for the production of the aforementioned materials.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: February 18, 2020
    Assignee: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
    Inventors: Eric Holmes, Gary Ostrander
  • Patent number: 10557852
    Abstract: This invention is directed to monomolecular sensors, comprising a selective binder, a non-selective binder and a fluorophore, which can track changes that occur on the surface of labeled proteins. This invention is further directed to the use of such sensors for identifying binding partners of specific proteins. This invention is further directed to His-tag binding compounds and uses thereof in the preparation of genetically targeted detectable molecules and sensors which can specifically bind tag-labeled proteins.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: February 11, 2020
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: David Margulies, Leila Motiei, Naama Mankovski, Yael Nissinkorn
  • Patent number: 10551390
    Abstract: Provided are artificially synthesized modified mono-methylated lysines and modified mono-methylated lysine derivatized polypeptides. Also provided is an antibody produced by using this modified mono-methylated lysine and modified monomethylated lysine derivatized polypeptide as an antigen, the antibody can be used in recognizing and enriching the modified polypeptide after the lysine mono-methylated polypeptide being derivatized in vitro. Also provided are a preparation method of said antibody, a method for identifying and quantifying the lysine mono-methylated modified substrate in cell or tissue by using proteomics approach of affinity enrichment for specific antibody and mass spectrometry.
    Type: Grant
    Filed: July 18, 2015
    Date of Patent: February 4, 2020
    Assignee: PMT Biolabs Inc.
    Inventor: Zhongyi Cheng
  • Patent number: 10545138
    Abstract: Processes and compositions are described for preparing new, colloidally stable, coated nanomagnetic particles useful for both in-vitro and in-vivo biomedical applications, including cell targeting and capturing cells, microorganisms, and cellular organelles or entities such as exosomes. These nanomagnetic particles can also be used as imaging contrast agents due to their small size and high magnetic moment. The nanomagnetic particles include a series of sequentially added, stabilizing surface coatings rendered onto nano-sized magnetic crystal clusters (e.g., magnetite particles) to impart colloidal stability in complex biological samples with minimal leaching of the coating materials, high binding capacity, and low non-specific binding. Another benefit of this invention is the ability to utilize both external and internal magnetic field-generating separation devices to effect separation of the magnetic nanoparticles.
    Type: Grant
    Filed: April 30, 2016
    Date of Patent: January 28, 2020
    Assignee: BioLegend, Inc.
    Inventors: Dhanesh Gohel, Hong Zhang, John Ransom
  • Patent number: 10545077
    Abstract: The present disclosure provides an extraction coating for an SPME sampling instrument, where the extraction coating includes a sorptive material immobilized in a fluorocarbon polymer that is compatible with thermal-assisted desorption techniques, solvent-assisted desorption techniques, or both. The disclosure also provides SPME sampling instruments, methods of making an SPME sampling instrument, and methods of extracting an analyte from a sample matrix using the SPME coating.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: January 28, 2020
    Assignee: JP SCIENTIFIC LIMITED
    Inventors: Janusz Boleslaw Pawliszyn, Emanuela Gionfriddo, Ezel Boyaci
  • Patent number: 10538549
    Abstract: NNA-derived specific adducts represent an integrated biomarker of exposure to thirdhand smoke (THS) as NNA is unique to THS. The NNA-dG covalent binding adduct could serve as such a biomarker, and play a role in identifying individuals exposed to THS, thus providing critical information for early detection and prevention.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: January 21, 2020
    Assignee: The Regents of the University of California
    Inventors: Bo Hang, Ahmed Chenna
  • Patent number: 10539567
    Abstract: Disclosed are methods for detecting remnant cancer cells in a tissue sample.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: January 21, 2020
    Assignee: Indicator Systems International, Inc.
    Inventors: Gerald F. Swiss, John V. Fante, Robert M. Moriarty, Richard J. Pariza
  • Patent number: 10533947
    Abstract: The present disclosure provides semiconductor-metal composite nanoparticles with optical properties that are superior to those of pure materials for use as contrast agents. The composites include noble metal nanoparticles having a layer of linker molecules being bound to the surface of the noble metal nanoparticle and a layer of dye molecules bound to the layer of linker molecules. The dye molecules are selected such that they form an ordered structure that exhibits a collective absorption band shift, compared to the individual dye molecule, when bound to the noble metal nanoparticle. This structure is encapsulated in a stabilizing coating layer forming a multi-shell structure with properties suitable for biosensing and other detection applications which exhibit enhanced Raman scattering compared to nanoparticles having dye molecules bound thereto not in the ordered structure.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: January 14, 2020
    Inventors: Colin R Zamecnik, Gilbert C Walker
  • Patent number: 10520495
    Abstract: This invention relates to a rare earth nanomaterial labeled biomolecule, its labeling method and a dissolution-enhanced time-resolved fluoroimmunoassay based on the rare earth nanomaterial. The rare earth nanomaterial serves as a label having stable properties, large specific surface area, strong modifiability, low-cost and thousands of lanthanide ions contained in each nanocrystal, the labeling ratio of rare earth ions can be greatly improved.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: December 31, 2019
    Assignee: FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER, CHINESE ACADEMIC OF SCIENCES
    Inventors: Xueyuan Chen, Shanyong Zhou, Wei Zheng, En Ma, Mingdong Huang, Zhuo Chen, Datao Tu
  • Patent number: 10509039
    Abstract: Provided are: a phosphor-integrated nanoparticle labeling agent which is capable of yielding a sufficient signal intensity even when its final concentration in an immunofluorescent staining reaction system is low (e.g., 0.02 nM) and enables to obtain an immunofluorescently stained image with reduced noise by inhibiting non-specific adsorption of a probe biological substance and a label to substances other than a detection subject; and an immunostaining method using the same. The phosphor-integrated nanoparticle labeling agent is a set which includes: a probe biological substance 3, which is linked to a first binding group substance A via a first hydrophilic polymer-derived spacer 1 having a length of 30 ? to 1,000 ? and specifically binds to a biomolecule 2; and a phosphor-integrated nanoparticle 5, which has a second binding group substance B capable of specifically binding to the first binding group substance A.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: December 17, 2019
    Assignee: KONICA MINOLTA, INC.
    Inventors: Hideki Gouda, Masaru Takahashi
  • Patent number: 10508234
    Abstract: A hydroxyl-covered silicon quantum dot nanoparticle having a silicon core, a plurality of silicon quantum dots, and a plurality of hydrocarbon chains is illustrated. A first portion of a surface associated with the silicon core is passivated by a plurality of silicon hydroxyl groups (Si—OH). The silicon quantum dots are attached to a second portion of the surface associated with the silicon core. The hydrocarbon chains are bonded to each of the silicon quantum dots through a plurality of silicon carbide bonds (Si—C), wherein each termination of the hydrocarbon chains has a carbon hydroxyl group (C—OH), such that the hydroxyl-covered silicon quantum dot nanoparticle is thoroughly covered by the carbon hydroxyl groups (C—OH) and the silicon hydroxyl groups (Si—OH).
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: December 17, 2019
    Assignee: NATIONAL CHIAO TUNG UNIVERSITY
    Inventors: Chang-Ching Tu, Kuang-Po Chen, Yaw-Kuen Li
  • Patent number: 10488401
    Abstract: Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: November 26, 2019
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Ronghui Lin